SOUTH PLAINFIELD, N.J., June 1 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced that Clare Kennedy has been appointed as Vice President of Commercial Operations. In this role, she will report to Theresa Natalicchio, Senior Vice President, Commercial, and will be responsible for PTC's patient services and distribution functions focusing on product access and reimbursement.
"We are delighted to welcome Clare to our management team," said Ms. Natalicchio. "Clare's extensive expertise in national healthcare customer management, contracting and distribution will be a great asset as we expand our commercial organization and prepare for the launch of ataluren."
"I am excited to join PTC," commented Ms. Kennedy. "The company has shown an exemplary advancement of its diverse pipeline and I look forward to being part of the commercial organization with a goal to bring PTC's innovative therapies to patients."
Prior to joining PTC, Ms. Kennedy spent 16 years at Pfizer, most recently as Vice President of Account Planning, overseeing national account management, customer contracting and product access in the U.S. for the company's $21 billion portfolio. Ms. Kennedy was responsible for U.S. sales in various areas including commercial health plans, pharmacy benefit management companies, long-term care, employers, and federally-funded programs. Prior to Pfizer, Ms. Kennedy started several small businesses involved in preventive health care and clinical research. She received an A.A.S. in Nursing from Long Island College Hospital, a B.S. in Health Science from
About PTC Therapeutics, Inc.
PTC is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary, small-molecule drugs that target post-transcriptional control of RNA processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC's internally-discovered pipeline addresses multiple therapeutic areas, including genetic disorders, oncology, and infectious diseases. PTC has extensive knowledge of post-transcriptional control processes and has developed proprietary technologies that it applies in its drug discovery activities internally and in collaborations with leading biopharmaceutical companies such as Genzyme, Pfizer, Celgene, Gilead and Schering-Plough. For more information, visit the company's Web site at www.ptcbio.com.
|SOURCE PTC Therapeutics, Inc.|
Copyright©2009 PR Newswire.
All rights reserved